Biotech entity
Source depth averages 11.8 original sources per story, versus 3.7 across the same-window beat baseline. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. AppLovin is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Source depth averages 11.8 original sources per story, versus 3.7 across the same-window beat baseline. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. AppLovin is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. That works out to roughly 0.2 stories per week across a 168-day span. The 7 average consequence score is above the beat benchmark of 6.2 in the same window. This profile follows 4 Biotech stories mentioning Federal Reserve across the period from February 18, 2026 to August 4, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 684 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Federal Reserve. Shared-story counts are live from our verified record — not editorial picks.
Pharma and Corporate Shifts
Strides Pharma announces ibuprofen recall; Compass drops Zillow lawsuit to focus on operations.
Global Contagion
Asian and European markets sell off; Planet Labs reports widening Q4 losses.
Legal and Macro Shock
Arizona files criminal charges against Kalshi; Jerome Powell issues hawkish inflation warnings.
Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors.
Arizona has initiated criminal proceedings against prediction market Kalshi for alleged illegal betting, occurring simultaneously with a global market downturn triggered by Federal Reserve inflation warnings. In the pharmaceutical sector, Strides Pharma has issued a recall for children's ibuprofen, highlighting operational risks during a period of heightened regulatory and economic pressure.
A new Morgan Stanley report identifies 'affordability politics' as a primary risk for the pharmaceutical sector ahead of the 2026 midterm elections. The firm warns that targeted legislative measures to lower prescription drug costs could create significant pricing pressure on high-margin brand-name drugs.
US equities faced a volatile session as investors reassessed the 'dark side' of AI disruption, dragging the Nasdaq into its fifth consecutive week of losses. Within the healthcare sector, attention is fixed on Medtronic's earnings and Masimo's performance as the industry grapples with shifting valuations.
Source: Benzinga · Yahoo Finance
Federal Reserve is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
